Loading
MAPK11 (Mitogen-activated protein kinase 11) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer.
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK11 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as pro-inflammatory cytokines or physical stress leading to direct activation of transcription factors. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each.
Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.91, genetic association 0.07, clinical 0.95).
In plain words · MAPK11 (Mitogen-activated protein kinase 11) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer.
MAPK11 (Mitogen-activated protein kinase 11) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer.
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway.
No product in this corpus aims at MAPK11 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA MAPK11: RNA tissue enhanced (brain 63 nTPM); high antibody staining in 7 normal tissues; highest cancer staining endometrial cancer (10 of 12 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Colorectal cancer); Open Targets associates it with 1 specific cancer type at or above 0.5 (colorectal cancer). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas MAPK11 tissue; Open Targets ENSG00000185386 associations
First described 1996. Earliest sequence paper UniProt cites for the protein: Jiang et al, J. Biol. Chem, 1996, "Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta)". Source.
Sources: HGNC HGNC:6873 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q15759 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000185386 (association with cancer (MONDO_0004992) 0.61; per-cancer scores at or above 0.5: colorectal cancer 0.58 (GraphQL API, CC0))
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK11 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as pro-inflammatory cytokines or physical stress leading to direct activation of transcription factors. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each. MAPK11 functions are mostly redundant with those of MAPK14. Some of the targets are downstream kinases which are activated through phosphorylation and further phosphorylate additional targets. RPS6KA5/MSK1 and RPS6KA4/MSK2 can directly phosphorylate and activate transcription factors such as CREB1, ATF1, the NF-kappa-B isoform RELA/NFKB3, STAT1 and STAT3, but can also phosphorylate histone H3 and the nucleosomal protein HMGN1. Location: Cytoplasm; Nucleus (UniProt). Locus 22q13.33 (HGNC).
RNA: tissue enhanced (brain 63 nTPM), detected in all normal tissues.
Medium: Adipose tissue, Adrenal gland, Appendix, Breast, Bronchus, Caudate, Cervix, Colon.
Medium only: glioma, head and neck cancer, ovarian cancer.
HPA MAPK11 tissue · HPA MAPK11 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"MAPK11" OR ABSTRACT:"MAPK11" OR TITLE:"mitogen-activated protein kinase 11" OR ABSTRACT:"mitogen-activated protein kinase 11" OR TITLE:"Mitogen-activated protein kinase 11" OR ABSTRACT:"Mitogen-activated protein kinase 11" OR TITLE:"p38-2" OR ABSTRACT:"p38-2" OR TITLE:"p38Beta" OR ABSTRACT:"p38Beta" OR TITLE:"SAPK2" OR ABSTRACT:"SAPK2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MAPK11, not a curated reading list.